Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Focused on the delivery of biostatistics projects. Several complementary options are being pursued simultaneously to build out this new capability and a further update will be provided to the market towards the end of the current financial year
Dr Putcha was appointed as Head of Bio-statistics on 3rd October, 2023. Over six months later and we have heard nothing and he does not appear on the list of Team members on the company website
Maybe he is being kept back for the big Bio-statistics update promised sometime before 30th June ?
I have reached out to them, but apart from a cordial reply, nothing about the subject in hand.
I can only go on the reply JM gave to a IM some months ago about why BOD dont see buying stock as the best way to grow the business?
Be interesting to hear Ant15's take on this?
Meanwhile, are we heading sub 1p?
Not as yet, but will consider doing so
If you don't mind me asking have you set out your thoughts to Peter? It sounds like he'd be receptive to shareholders
I have noted this before, but there is a similarity in parts of the wording used by Physiomics and Valirx. I feel it is not a coincidence. Here is the latest example :
PYC tweet 4th April 'Our latest news roundup .....' whilst Valirx tweet 9th April 'Welcome to the latest edition of our news roundups'
JM commented in the most recent IMC presentation that 'our financial and operational success is not dependent on what happens at Valirx'. I would take this to mean that there are no imminent plans for any closer ties between the two, which is good to know
Very early days I know, but the benchmark by which I will be judging Peter Sargent's performance as CEO is the company share price. Price on the trading day immediately before he was appointed (21st January) was 1.80. Price now 1.10
I like what I have seen and heard to date in his presentations and I am hoping that this now starts to feed through to the share price and we get back to at least the pre-appointment levels by financial year end. Some quality RNS releases are
what is now needed
Extremely disappointed that Angel Investor and NED Shalabh Kumar has not put his hand in his pocket and taken a decent chunk of shares by now Same for the rest of the Board of Directors who are happy to accept free options or take shares in a knock-down placing but show no enthusiasm for investing at full price like the rest of us lesser mortals
It would be an excellent way for the BOD to prove to the new Principal Consultant - Head of Modelling in no uncertain terms that they genuinely have big ambitions for growing not only sales but, more importantly, shareholder value
Biostatistics service line
The Company was excited to announce its intention to develop a separate consulting service line focused on the delivery of biostatistics projects. Several complementary options are being pursued simultaneously to build out this new capability and a further update will be provided to the market towards the end of the current financial year. We anticipate that, if successful, this new service line could make a material contribution to the Company's revenues
Ant
I share that view too, plus the biostatistics division looks very exciting and Peter wording interesting
Added a few more this am I think the DoseMe Rx is a game changer .
Ýes, everything Peter has mentioned looks exciting and more ìmportantky they are one of only a few AIM companies actually growing and close to break even
I agree. Patience should be well rewarded IMO
Thankyou
It's hard to believe you can have c£900,000 revenues for full year (confirmed as being likely to be achieved twice) an a Conservative pipeline of £1,500,000 amd yet the entire business valued at only £1.5mln!
Project runs until October 2025. Presumably there will be indications much earlier as to the success of the trials
Good morning Trench
Is there an end date for the trials please ?
Interesting that DoseMeRx have reposted this PYC tweet :
'Check out this insightful article from our partner @DoseMeApp highlighting the vital role of #precisionmedicine in #oncology and beyond'
I feel that a commercial deal between the two companies is likely if the G-CSF trials go well
Same here, I have close to 1% and holding
Likewise Andrew I'm currently holding over 1% and have no intention of selling!
Hello Andrew
Ridiculous were only trading on 1.5 x expected earning !!
Hi Laura,
Have just done the same. Long term holder, can see some momentum here for the first time in a while. I like how positive Peter has been in recent months, which adds to my confidence levels!
With revenues expected to be £900,000- 1mln and pipeline increased to £1.5mln I have used some of the new ISA money to add more
Evidence-based interventions, such as improved early detection and education programmes, will help to save lives and prevent ill health from prostate cancer in the years to come,” added James, a professor of prostate cancer research at the Institute of Cancer Research, London, and a consultant clinical oncologist at the Royal Marsden NHS foundation trust.
James said there was a global need for new and improved ways to test for the disease, to reduce overdiagnosis and overtreatment while detecting potentially lethal tumours earlier
This brings PYC technology well into focus
https://www.theguardian.com/society/2024/apr/04/prostate-cancer-cases-worldwide-diagnoses-deaths-2040-study
Nice summary again,really nice to have mew ideas / points of view